Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CNTA NASDAQ:IBRX NASDAQ:KNSA NASDAQ:KROS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNTACentessa Pharmaceuticals$16.81-2.1%$13.90$9.10▼$19.09$2.25B1.481.08 million shs851,202 shsIBRXImmunityBio$2.37-3.7%$2.79$1.83▼$7.48$2.09B0.127.83 million shs7.04 million shsKNSAKiniksa Pharmaceuticals International$31.98+5.7%$28.38$17.82▼$32.15$2.33B0.14665,304 shs1.07 million shsKROSKeros Therapeutics$14.32$14.05$9.12▼$72.37$581.68M1.33461,332 shs261,048 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNTACentessa Pharmaceuticals0.00%+9.09%+17.27%+23.88%+66.93%IBRXImmunityBio0.00%-17.13%-12.22%+12.86%-49.36%KNSAKiniksa Pharmaceuticals International0.00%+21.46%+14.81%+15.12%+27.36%KROSKeros Therapeutics0.00%-0.97%+7.43%-1.65%-70.86%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCNTACentessa Pharmaceuticals3.1642 of 5 stars3.53.00.00.02.63.30.6IBRXImmunityBio2.2569 of 5 stars3.61.00.00.02.71.70.6KNSAKiniksa Pharmaceuticals International3.388 of 5 stars3.53.00.00.03.73.30.6KROSKeros Therapeutics2.5857 of 5 stars3.32.00.00.03.43.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCNTACentessa Pharmaceuticals 3.00Buy$28.1067.16% UpsideIBRXImmunityBio 3.20Buy$12.25416.88% UpsideKNSAKiniksa Pharmaceuticals International 3.00Buy$41.1728.73% UpsideKROSKeros Therapeutics 2.50Moderate Buy$30.56113.38% UpsideCurrent Analyst Ratings BreakdownLatest KROS, CNTA, KNSA, and IBRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/30/2025CNTACentessa PharmaceuticalsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.007/29/2025KNSAKiniksa Pharmaceuticals InternationalJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$45.00 ➝ $54.007/25/2025IBRXImmunityBioD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.007/21/2025CNTACentessa PharmaceuticalsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$30.007/21/2025KNSAKiniksa Pharmaceuticals InternationalWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$36.007/9/2025KNSAKiniksa Pharmaceuticals InternationalWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$30.00 ➝ $42.007/8/2025IBRXImmunityBioD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.006/10/2025KROSKeros TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$32.00 ➝ $18.006/4/2025IBRXImmunityBioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.006/3/2025IBRXImmunityBioD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.005/30/2025KROSKeros TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$15.00(Data available from 8/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCNTACentessa Pharmaceuticals$6.85M327.91N/AN/A$3.05 per share5.51IBRXImmunityBio$14.74M141.91N/AN/A($0.57) per share-4.16KNSAKiniksa Pharmaceuticals International$423.24M5.51N/AN/A$6.60 per share4.85KROSKeros Therapeutics$3.55M163.85N/AN/A$14.11 per share1.01Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCNTACentessa Pharmaceuticals-$235.76M-$1.81N/AN/AN/AN/A-40.22%-29.95%8/12/2025 (Estimated)IBRXImmunityBio-$413.56M-$0.58N/AN/AN/A-1,310.30%N/A-121.88%8/11/2025 (Estimated)KNSAKiniksa Pharmaceuticals International-$43.19M$0.04799.70127.92N/A0.90%1.05%0.80%N/AKROSKeros Therapeutics-$187.35M-$0.18N/AN/A2.591.96%0.75%0.69%8/6/2025 (Estimated)Latest KROS, CNTA, KNSA, and IBRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025CNTACentessa Pharmaceuticals-$0.34N/AN/AN/AN/AN/A8/11/2025Q2 2025IBRXImmunityBio-$0.10N/AN/AN/A$21.95 millionN/A8/6/2025Q2 2025KROSKeros Therapeutics-$1.13N/AN/AN/A$3.83 millionN/A7/29/2025Q2 2025KNSAKiniksa Pharmaceuticals International$0.18$0.23+$0.05$0.23$145.21 million$156.80 million5/12/2025Q1 2025CNTACentessa Pharmaceuticals-$0.35-$0.20+$0.15-$0.20N/AN/A5/12/2025Q1 2025IBRXImmunityBio-$0.12-$0.15-$0.03-$0.15$17.50 million$16.52 million5/6/2025Q1 2025KROSKeros Therapeutics-$0.01$3.62+$3.63$3.62$84.62 million$211.25 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCNTACentessa PharmaceuticalsN/AN/AN/AN/AN/AIBRXImmunityBioN/AN/AN/AN/AN/AKNSAKiniksa Pharmaceuticals InternationalN/AN/AN/AN/AN/AKROSKeros TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCNTACentessa Pharmaceuticals0.2814.3714.37IBRXImmunityBioN/A2.222.05KNSAKiniksa Pharmaceuticals InternationalN/A3.573.16KROSKeros TherapeuticsN/A19.2919.29Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCNTACentessa Pharmaceuticals82.01%IBRXImmunityBio8.58%KNSAKiniksa Pharmaceuticals International53.95%KROSKeros Therapeutics71.56%Insider OwnershipCompanyInsider OwnershipCNTACentessa Pharmaceuticals7.09%IBRXImmunityBio76.79%KNSAKiniksa Pharmaceuticals International53.48%KROSKeros Therapeutics22.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCNTACentessa Pharmaceuticals200133.62 million124.15 millionOptionableIBRXImmunityBio590882.62 million204.86 millionOptionableKNSAKiniksa Pharmaceuticals International22072.97 million33.95 millionOptionableKROSKeros Therapeutics10040.62 million31.31 millionOptionableKROS, CNTA, KNSA, and IBRX HeadlinesRecent News About These CompaniesFederated Hermes Inc. Grows Position in Keros Therapeutics, Inc. (NASDAQ:KROS)August 3 at 3:52 AM | marketbeat.comKeros Therapeutics (KROS) Projected to Post Earnings on WednesdayJuly 31, 2025 | marketbeat.comKeros Therapeutics, Inc. (NASDAQ:KROS) Given Consensus Rating of "Moderate Buy" by AnalystsJuly 31, 2025 | marketbeat.comKROS vs. EXAS: Which Stock Should Value Investors Buy Now?July 28, 2025 | zacks.comCorton Capital Inc. Makes New $186,000 Investment in Keros Therapeutics, Inc. (NASDAQ:KROS)July 28, 2025 | marketbeat.comKeros Therapeutics Announces the First Patient Dosing in the Phase 3 RENEW Clinical Trial of ElriterceptJuly 17, 2025 | globenewswire.comKeros Therapeutics, Inc. (NASDAQ:KROS) Receives Consensus Rating of "Moderate Buy" from BrokeragesJuly 6, 2025 | marketbeat.comB of A Securities Downgrades Keros Therapeutics (KROS)June 11, 2025 | msn.comKeros Therapeutics' Quiet Near-Term Outlook Overshadows Pipeline Potential: AnalystJune 10, 2025 | uk.finance.yahoo.com3KROS : Keros Therapeutics' Quiet Near-Term Outlook Overshadows Pipeline...June 10, 2025 | benzinga.comActivist investor demands Keros 'aggressively' cut costs just weeks after layoffsJune 10, 2025 | fiercebiotech.comFKeros Therapeutics, Inc.: Keros Announces Return of $375 Million in Excess Capital to StockholdersJune 9, 2025 | finanznachrichten.deKeros To Return $375M to Investors After Shareholder Activism, Safety SignalJune 9, 2025 | biospace.comBADAR1 Issues Statement on Keros Therapeutics' Troubling 2025 Director Election Results and Insufficient Capital Return ProposalJune 9, 2025 | prnewswire.comKeros Announces Return of $375 Million in Excess Capital to StockholdersJune 9, 2025 | globenewswire.comAnalysts Are Bullish on Top Healthcare Stocks: Icon (ICLR), Keros Therapeutics (KROS)June 7, 2025 | theglobeandmail.comKeros Therapeutics Announces Participation at Goldman Sachs 46th Annual Global Healthcare ConferenceJune 6, 2025 | globenewswire.comKeros Therapeutics Discontinues Cibotercept Development in PAH and Announces Corporate RestructuringMay 30, 2025 | nasdaq.comAfter Safety Stumbles, Keros Axes Pulmonary Hypertension Drug, 45% of StaffMay 30, 2025 | biospace.comBKeros Therapeutics, Inc. (KROS) Halts PAH Drug Development After Safety Concerns in TROPOS TrialMay 29, 2025 | insidermonkey.comBofA says Keros cost reduction 'disappoints,' still sees reasons to like storyMay 29, 2025 | thefly.comTNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKROS, CNTA, KNSA, and IBRX Company DescriptionsCentessa Pharmaceuticals NASDAQ:CNTA$16.81 -0.36 (-2.10%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$16.00 -0.81 (-4.82%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.ImmunityBio NASDAQ:IBRX$2.37 -0.09 (-3.66%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$2.37 +0.00 (+0.17%) As of 04:06 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.Kiniksa Pharmaceuticals International NASDAQ:KNSA$31.98 +1.72 (+5.68%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$33.50 +1.52 (+4.74%) As of 04:09 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.Keros Therapeutics NASDAQ:KROS$14.32 0.00 (0.00%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$15.00 +0.68 (+4.75%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale Is PG&E an AI Power Play? Why Options Traders Are Betting Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
